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Cerebral influx of  Na+ and  Cl− 
as the osmotherapy-mediated rebound 
response in rats
Eva Kjer Oernbo1, Kasper Lykke1,5, Annette Buur Steffensen1, Kathrin Töllner2,3, Christina Kruuse4, 
Martin Fredensborg Rath1, Wolfgang Löscher2,3 and Nanna MacAulay1,6* 
Abstract 
Background: Cerebral edema can cause life-threatening increase in intracranial pressure. Besides surgical craniec-
tomy performed in severe cases, osmotherapy may be employed to lower the intracranial pressure by osmotic extrac-
tion of cerebral fluid upon intravenous infusion of mannitol or NaCl. A so-called rebound effect can, however, hinder 
continuous reduction in cerebral fluid by yet unresolved mechanisms.
Methods: We determined the brain water and electrolyte content in healthy rats treated with osmotherapy. Osmo-
therapy (elevated plasma osmolarity) was mediated by intraperitoneal injection of NaCl or mannitol with inclusion of 
pharmacological inhibitors of selected ion-transporters present at the capillary lumen or choroidal membranes. Brain 
barrier integrity was determined by fluorescence detection following intravenous delivery of  Na+-fluorescein.
Results: NaCl was slightly more efficient than mannitol as an osmotic agent. The brain water loss was only ~ 60% of 
that predicted from ideal osmotic behavior, which could be accounted for by cerebral  Na+ and  Cl− accumulation. This 
electrolyte accumulation represented the majority of the rebound response, which was unaffected by the employed 
pharmacological agents. The brain barriers remained intact during the elevated plasma osmolarity.
Conclusions: A brain volume regulatory response occurs during osmotherapy, leading to the rebound response. 
This response involves brain accumulation of  Na+ and  Cl− and takes place by unresolved molecular mechanisms that 
do not include the common ion-transporting mechanisms located in the capillary endothelium at the blood–brain 
barrier and in the choroid plexus epithelium at the blood–CSF barrier. Future identification of these ion-transporting 
routes could provide a pharmacological target to prevent the rebound effect associated with the widely used 
osmotherapy.
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Background
The ion and fluid homeostasis in the mammalian brain 
is tightly controlled to preserve the intracranial pressure 
(ICP) within a normal range. Cerebral edema, as occur-
ring in pathologies such as traumatic brain injury and 
stroke, can cause the ICP to rise to life-threateningly high 
levels [1]. In severe cases, a decompressive craniectomy 
can be initiated to lower the ICP [2]. Alternatively, osmo-
therapy can be used to osmotically extract cerebral fluid 
into the blood circulation by intravenous (i.v.) infusion of 
mannitol or NaCl [3], although it remains disputed which 
of these osmotic agents is most efficient for brain water 
extraction. The initial target when applying osmotherapy 
is a plasma osmolarity up to 320  mOsm but depending 
on the clinical circumstances, this recommended value 
may be exceeded [1]. Osmotherapy induces an immedi-
ate loss of brain fluid, which can, however, be reduced 
or even reversed due to yet incompletely understood 
mechanisms; a phenomenon referred to as the rebound 
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effect [4, 5]. The rebound effect has been suggested to 
arise from a compensatory accumulation of cerebral 
osmolytes, generating an osmotic gradient favoring fluid 
movement back into the brain particularly upon dilution 
of the plasma osmolarity by renal excretion and/or with-
drawal of the osmotic agent [4, 5]. It remains uncertain 
to what extent brain ion accumulation participates in the 
rebound response, and if so, which molecular transport-
ing mechanisms contribute to this volume regulatory 
response. The secretion of ions may take place at one or 
both of the two major interfaces between the brain and 
blood: the capillary endothelium forming the blood–
brain barrier (BBB) and/or the cerebrospinal fluid (CSF)-
secreting choroid plexus epithelium, which forms the 
blood–CSF barrier (BCSFB) [6, 7]. The capillary endothe-
lium and the choroid plexus epithelium express several 
ion-transporting mechanisms, i.e. the  Na+–K+–2Cl− 
co-transporter 1 (NKCC1), the  Na+–H+ anti-porter 1 
(NHE1),  Na+-coupled bicarbonate transporters (NBCs), 
and the amiloride-sensitive  Na+ channel (ENaC) [8–10]. 
These transport mechanisms may be potential candi-
dates for brain ion and water regulation, and could, as 
such, participate in electrolyte translocation from blood 
to brain during the elevated blood osmolarity resulting 
from osmotherapy treatment. Inhibition of a subset of 
these ion transporters has been associated with improved 
outcome in an experimental animal model of stroke [11, 
12], which may indicate involvement of such transport 
mechanisms in brain ion and water dynamics. Here, we 
employed in  vivo investigations of healthy non-edema-
tous rats to obtain the brain volume regulatory response 
to increased plasma osmolarity in the absence of patho-
logical events, such as stroke/haemorrhage, and investi-
gate a putative role of a range of transport mechanisms in 
the brain volume regulatory gain of ions.
Methods
Animals
This study was performed in accordance with the Euro-
pean Community guidelines for the use of experimental 
animals using protocols approved either by the Lower 
Saxony State Office for Consumer Protection and Food 
Safety (Niedersachsen, Germany) or Supervisory Author-
ity on Animal Testing (Danish Veterinary and Food 
Administration, Denmark). To avoid variation due to 
mixed gender, only female Sprague–Dawley rats were 
employed, aged 9–13 weeks (Taconic A/S, Lille Skensved, 
Denmark or Janvier Labs, Le Genest-Saint-Isle, France). 
Whether the present findings hold for male rats as well 
will require further studies in the future. Rats were 
housed in groups of 2–5 per cage (Tp III cages, 22  °C, 
12:12  h light/dark cycle) with access to unlimited water 
and standard altromin rodent diet. The allocation of rats 
into the treatment groups was randomized, and all exper-
iments were reported in compliance with the ARRIVE 
guidelines (Animal Research: Reporting in Vivo Experi-
ments) [13].
Brain water extraction by elevated plasma osmolarity
Rats were anesthetized using isoflurane inhalation mixed 
in  O2 (1.5–5%, 1 l/min) and anaesthesia was maintained 
throughout the entire experiment. The body tempera-
ture was controlled to 37  °C using an electric heating 
pad (Harvard Apparatus, Holliston, MA, US) and moni-
tored by a rectal probe during the entire procedure. 
To avoid systemic regulation of blood osmolytes upon 
hyperosmotic treatment, a functional nephrectomy 
was performed immediately prior to the initiation of 
the experiment in all animals except for naïve animals, 
which were not exposed to isosmolar- or hyperosmolar 
treatment but underwent anaesthesia induction shortly 
before decapitation, see Table  1 for grouping of experi-
mental animals. In brief, laparotomy incision areas were 
treated with local analgesia [2–4 drops 2% tetracaine 
(Sigma-Aldrich, Brøndbyvester, Denmark, T7508) or 
xylocaine (1  mg/ml, AstraZeneca A/S, Copenhagen, 
Denmark, N01BB02)/bupivacaine (0.5  mg/ml, Amgros 
I/S, Copenhagen, Denmark, N01BB01) (both in 0.9% w/v 
NaCl)] prior to opening of the abdominal cavity either 
from the dorsal or the ventral side in the fully anesthe-
tized animals. The renal artery and vein were ligated 
using non-absorbable suture. For rats given ventral inci-
sion, a catheter (for i.p. delivery, see below) was placed 
during suturing of the incision, while for rats with dorsal 
incisions, the smaller openings were closed with metal 
wound clamps immediately after i.p. delivery. The rats 
received a single i.p. bolus of a physiological NaCl solu-
tion (0.9% w/v NaCl) as an isosmolar control treatment, 
while an equiosmolar bolus of NaCl (1.17 g/kg, 1 M [14]) 
or mannitol (7.29 g/kg, dissolved in 0.9% w/v NaCl; 2 M) 
was given to elevate the plasma osmolarity to a similar 
extent. All solutions were heated to 37  °C and delivered 
as 2  ml/100  g body weight. We employed i.p. delivery 
of the osmotic agent as this delivery route gives similar 
plasma osmolarities as i.v. delivery [14]. For i.v. inhibi-
tor experiments, a catheter was inserted into the tail 
vein and an inhibitor mixture containing bumetanide 
(10 mg/kg [11], Sigma-Aldrich, B3023), amiloride (6 mg/
kg [15], Sigma-Aldrich, A7410), and methazolamide 
(20  mg/kg [16], Sigma-Aldrich, SML0720) or vehicle 
(specified below) was injected 5  min prior to i.p. treat-
ment with isosmolar- or hyperosmolar NaCl, see Table 1 
for grouping of experimental animals. Inhibitors were 
given in a mixture to minimize the number of rats used 
for experiments. While drug concentrations in the blood 
are difficult to assess due to unspecific binding to tissue 
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and blood proteins, we estimate maximal blood concen-
trations of 0.4  mM for bumetanide and amiloride, and 
1.2  mM for methazolamide based on estimated blood 
volume of 7% of the rat body weight (average: 233 g). In 
a few experiments, rats were given a triple inhibitor or 
vehicle dose into the tail vein. In this case, a bolus injec-
tion of inhibitors or vehicle was given 20 min and 5 min 
before and 15 min after delivery of isosmolar or hyperos-
molar NaCl. In other experiments, rats were positioned 
in a stereotactic frame (Stoelting, Wood Dale, IL, US, 
51500) and a micro drill (CircuitMedic, Haverhill, MA, 
US, 110-4102) employed to induce a burr hole in the 
skull (coordinates from bregma: 1.4 mm lateral, 0.8 mm 
posterior). A Hamilton syringe (G27, Agntho’s AB, Lid-
ingö, Sweden, 2100521) filled with inhibitor mixture 
(bumetanide: 33  μM, amiloride and methazolamide: 
167 μM, final ventricular concentrations estimated to be 
20 and 100  μM [17–22]) or vehicle dissolved in equili-
brated (95%  O2/5%  CO2) artificial CSF (aCSF) (120 mM 
NaCl, 2.5  mM KCl, 1.3  mM  MgSO4 × 7  H2O, 1  mM 
 NaH2PO4, 25  mM  NaHCO3, 10  mM glucose × H2O, 
2.5 mM  CaCl2, pH 7.4 at 37 °C) was fastened to the ste-
reotactic apparatus and introduced into the right lateral 
ventricle (4.7  mm ventral). Two min prior to isosmolar 
or hyperosmolar i.p. treatment, 6 μl inhibitor or vehicle 
solution was injected in 2 s (volume and rate adjusted to 
hit both lateral ventricles), see Table  1 for grouping of 
experimental animals. To maintain an optimal intraven-
tricular inhibitor dose, inhibitor or vehicle solution was 
injected into the ventricular system every 15 min. All the 
experiments were terminated by decapitation of the ani-
mal 1 h after i.p. injection of osmotic agent or physiologi-
cal saline. A 1 h treatment period was chosen according 
to the reported near stabilization of plasma osmolarity 
and brain volume within 30  min after a hyperosmolar 
challenge [14]. All inhibitor solutions were made freshly 
each day (some from frozen stock solutions). Bumetanide 
and methazolamide were dissolved in 0.1 M NaOH (pH 
adjusted with 0.1  M HCl to pH 11 and 9, respectively) 
and diluted to 10  mg/ml for injection into the tail vein, 
while amiloride was dissolved in heated water at 10 mg/
ml. Inhibitors, which were introduced into the ventricu-
lar system, were dissolved in DMSO (final concentration 
of 0.2% in aCSF).
Brain water and electrolyte quantification
The brain was removed immediately after decapitation. 
The olfactory bulbs and medulla oblongata were dis-
carded and the remaining brain tissue was placed in a 
pre-weighed porcelain evaporation beaker and weighed 
within minutes after isolation to reduce loss of brain 
water. Brain tissue was homogenized in the pre-weighed 
evaporation beaker using a steel pestle and dried at 
100 °C for 3–4 days to a constant mass for determination 
of the brain water content. The dried brain tissue (75–
130 mg) was extracted in 1 ml 0.75 M  HNO3 on a hori-
zontal shaker table for 3 days at room temperature (RT). 
The  Cl− content in the brain extracts was quantified by 
Table 1 Overview of experimental animal groups
i.p., intraperitoneal; i.v., intravenous; i.c.v., intra(cerebro)ventricular; 3×, triple doses; NaFl,  Na+-fluorescein
Experiment Label Osmotic agent Treatment Delivery route # rats
Brain water and ion quantification Control – Vehicle i.v. 9
– Inhibitors i.v. 7
– Vehicle i.c.v. 6
– Inhibitors i.c.v. 6
Osmotherapy NaCl (i.p.) Vehicle i.v. 9
NaCl (i.p.) Inhibitors i.v. 8
NaCl (i.p.) 3× vehicle i.v. 4
NaCl (i.p.) 3× inhibitors i.v. 4
NaCl (i.p.) Vehicle i.c.v. 6
NaCl (i.p.) Inhibitors i.c.v. 6
Mannitol (i.p.) – – 6
Naïve – – – 3
Brain barrier permeability Control – NaFl i.v. 3
Osmotherapy NaCl (i.p.) NaFl i.v. 3
Naïve – – – 3
Monitoring of ICP – Evans blue i.c.v. 3
Blood pressure measurement – Vehicle i.v. 3
– Inhibitors i.v. 3
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a colorimetric method using a QuantiChrom™ Chloride 
Assay Kit (MEDIBENA Life Science & Diagnostic Solu-
tion, Vienna, Austria), while the  Na+ and  K+ content was 
quantified using flame photometry (Instrument Labora-
tory 943, Bedford, MA, US).
Plasma osmolarity and ion quantification
A heparin-coated tube (Jørgen Kruuse A/S, Langeskov, 
Denmark) was filled with pooled blood (venous and 
arterial) from the neck region upon decapitation of 
the rats. Blood samples were kept cold for maximal 
4 h until centrifugation at 1300g for 10 min at RT. The 
plasma layer was collected and stored at − 20  °C. The 
plasma osmolarity was determined by a freezing point 
depression osmometer (Löser, Berlin, Germany), while 
the content of  Na+,  Cl−, urea and creatinine was meas-
ured using a  RAPIDLab® blood gas analyzer (Siemens, 
Münich, Germany) or flame photometer (Instrument 
Laboratory 943).
Analysis of data
If assuming that the barriers between blood and brain 
behave as semipermeable membranes, i.e. permeable 
only to water but not to solutes, a new steady state in 
brain water content  Vh (h; hyperosmolar, in ml/g dry 
weight) mediated by an elevated plasma osmolarity Chosm 
(mOsm) can be given by Eq. 1 as described in [14], where 
 Vi is brain water content (i; isosmolar, in ml/g dry weight) 
in rats with isosmolar plasma osmolarity Ciosm (mOsm).
If the brain water loss is less than predicted by Eq.  1, 
this will imply that the brain gains osmotically active sol-
utes given that the plasma and brain water is in osmotic 
equilibrium. The predicted gain of electrolytes, ΔQ 
(mmol/kg dry weight), can then be given by
Brain barrier permeability
To assess the paracellular permeability of the brain 
barriers, anaesthetized rats were subjected to a func-
tional nephrectomy. The experiments were initiated 
as above, after which a 4%  Na+-fluorescein (Sigma-
Aldrich, F63772) solution (2  ml/kg, 0.25  ml/min, dis-
solved in 0.9% w/v NaCl) was infused into the femoral 
vein through a catheter;  Na+-fluorescein is a marker of 
paracellular permeability and has been used to identify 
paracellular BBB disruption by osmotic shock [23]. Five 
min hereafter, isosmolar or hyperosmolar NaCl was 
injected into the abdominal cavity as described above, 
(1)Vh = Vi ·
Ciosm
Chosm
(2)Q = Vh · Chosm − Vi · Ciosm
see Table  1 for grouping of experimental animals. Rats 
were decapitated after 1 h, and the brains were removed 
immediately and frozen on crushed solid  CO2. Coronal 
sections  (12  μm) were cut in a cryostat and mounted 
on slides.  Na+-fluorescein was visualized using an Axi-
oplan 2 epifluoresence microscope (Carl Zeiss Vision, 
München-Halbergmoos, Germany) equipped with a Plan 
Neofluar and an AxioCam MR digital camera by use of 
the AxioVision 4.4 software (Carl Zeiss Vision, Birkerød, 
Denmark). Image acquisition was performed in a blinded 
fashion. Representative images were captured of brain 
regions comprising the neocortex, hippocampus, thala-
mus, and the lateral ventricle. The pineal gland was used 
as an internal positive control due to its lack of BBB [24]. 
Phase contrast images were included to visualize brain 
structures in transmitted light. Image processing (bright-
ness and contrast) was performed using Adobe Photo-
shop (San Jose, CA, US).
Monitoring of ICP
In order to monitor the ICP of the anaesthetized rats, a 
micro drill (1 mm bit) was applied to manually induce a 
burr hole into the skull until transparency was observed. 
The thin skull layer was gently ruptured using a 0.6 mm 
bit (without disruption of dura mater) after which a 
tweezer was employed to remove skull flakes. An epi-
dural probe (Plastics One, Roanoke, VA, US, C313GS-5-
3UP, 0 mm below pedestal) was gently placed onto dura 
mater, and fastened to the skull by cement (GC, Kortrijk, 
Belgium, Fuji I, 000136). ICP fluctuations were detected 
by PicoLog Recorder software (Pico Technology, Cam-
bridgeshire, UK). To ensure proper probe insertion in 
the epidural space, the jugular vein was compressed 
before the beginning of each experiment and a raised 
ICP detected as a positive control. An Evans blue (Sigma-
Aldrich, E2129) solution (0.003% w/v in 0.9% w/v NaCl) 
was infused into the right lateral ventricle (6 μl in total, 
3  μl/s) using a Hamilton syringe, while ICP recordings 
were collected, see Table  1 for grouping of experimen-
tal animals. 10 min after intraventricular injections, rats 
were euthanized by decapitation. The brains were iso-
lated and cerebral hemispheres separated to confirm 
intraventricular Evans blue staining.
Blood pressure measurement
Female Sprague–Dawley rats (22–28 weeks) were anaes-
thetized with chloral hydrate (400  mg/kg, i.p.), see 
Table 1 for grouping of experimental animals. A catheter 
was inserted into the left femoral artery to measure the 
intra-arterial blood pressure (BioSys software, TSE Sys-
tems, Bad Homburg, Germany). The intra-arterial blood 
pressure was monitored until 1  h after i.v. injection of 
inhibitors (10 mg/kg bumetanide, 6 mg/kg amiloride and 
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20  mg/kg methazolamide) or vehicle, and experiments 
were terminated by decapitation of the rats.
Statistical analysis
All data are given as mean values ± standard error of 
mean (SEM). To evaluate statistically significant differ-
ences between mean values of two groups, an unpaired 
two-tailed Student’s t-test was applied, while a one-way 
analysis of variance (ANOVA) followed by Dunnett’s or 
Tukey’s multiple comparisons post hoc test was applied 
to compare mean values of multiple groups. Compari-
son of two factors was evaluated by a two-way ANOVA 
followed by Tukey’s multiple comparisons post hoc test. 
p < 0.05 was considered statistically significant. All sta-
tistical analyses were performed in GraphPad Prism 7.0 
(GraphPad Software, Inc., La Jolla, CA, US) and indicated 
in the respective figure legend.
Results
Osmotherapy caused cerebral water loss and influx of  Na+ 
and  Cl−
To determine the effect of osmotherapy on the brain 
water and electrolyte content, we employed a rat in vivo 
model in which the plasma osmolarity was elevated by 
i.p. injection of NaCl (1.17 g/kg, 2 ml/100 g body weight). 
To isolate the effect of brain volume regulation, rats were 
functionally nephrectomized prior to the procedure, the 
success of which was evident from the increased plasma 
content of creatinine and urea in these animals com-
pared to naïve rats, which had not undergone nephrec-
tomy (Fig. 1a, b, see figure legend for values). The plasma 
osmolarity in the nephrectomized rats treated with 
isosmolar NaCl (303 ± 1  mOsm, n = 9, termed ‘control’ 
henceforward) was not significantly different from that of 
the naïve rats (298 ± 1  mOsm, n = 3, Fig.  1c), indicating 
that the extended experimental protocol in itself did not 
interfere with plasma osmolarity. Following a single bolus 
injection with hyperosmotic NaCl (termed ‘osmotherapy’ 
henceforward), the plasma osmolarity was increased to 
355 ± 1 mOsm after 1 h (n = 9, p < 0.001, Fig. 1c), with an 
associated increase in the plasma content of  Na+ and  Cl− 
(n = 9, p < 0.001, Fig. 1d, e, see figure legend for values).
The brain water content of the naïve rats, which were 
not exposed to isosmolar or hyperosmolar treatment, 
(3.72 ± 0.03  ml/g dry weight, n = 3) was slightly lower 
than that of the control rats exposed to the isosmo-
lar NaCl treatment (3.79 ± 0.01  ml/g dry weight, n = 9, 
p < 0.05, Fig.  2a), while osmotherapy caused a 9% reduc-
tion in the brain water content (to 3.46 ± 0.01, n = 9, 
p < 0.001, Fig.  2a). However, this reduction in brain water 
content amounted to only ~ 60% of that predicted from 
ideal osmotic behavior (calculated according to Eq. 1 and 
illustrated as a dashed red line in Fig. 2a), which indicates 
that volume regulation takes place. The osmotherapy-
mediated reduction in the brain water loss was associated 
with an increase in brain electrolyte content, with a 15% 
increase in brain  Na+ (p < 0.001, Fig. 2b) and a 31% increase 
in brain  Cl− (p < 0.001, Fig.  2c) (see figure legend for val-
ues). There was a minor 2% increase in the brain  K+ con-
tent (control: 463 ± 2 mmol/kg dry weight vs. osmotherapy: 
471 ± 2 mmol/kg dry weight, n = 9, p < 0.05). The brain  Na+ 
and  Cl− content in control rats was not significantly differ-
ent from that obtained in naïve rats, Fig. 2b, c, see figure 
legend for values. The total increase in osmolyte content 
represented by  Na+,  Cl−, and  K+, ΔQobserved, amounted to 
79 mmol/kg dry weight, which represents 104% of the pre-
dicted osmolyte gain, ΔQpredicted = 76 mmol/kg dry weight 
(Eq. 2). The osmotherapy-mediated gain of brain  Na+ and 
 Cl−, and to a minor extent  K+, can thereby account for the 
reduction in brain water loss observed 1 h after administra-
tion of the hyperosmolar challenge.
NaCl is slightly more potent than mannitol in osmotherapy
To determine the potency of osmotherapy conducted with 
NaCl vs. mannitol, we performed a parallel experimental 
series with mannitol as the osmotic agent. The increased 
 Na+ and  Cl− plasma concentration observed with NaCl 
infusion (as above, p < 0.001), was absent, and even slightly 
reversed compared to control rats upon i.p. delivery of 
mannitol (7.29  g/kg, 2  ml/100  g body weight) (p < 0.001 
for  Na+ and p < 0.05 for  Cl−, Fig.  2d, e, see figure legend 
for values). Mannitol treatment yielded a plasma osmolar-
ity (356 ± 3  mOsm, n = 6) similar to that obtained in rats 
treated with NaCl (355 ± 1 mOsm, n = 9, Fig. 1c, p = 0.71). 
Mannitol efficiently reduced the brain water content (to 
3.51 ± 0.02  ml/g dry weight, p < 0.001), although slightly 
less effectively than NaCl (p < 0.05), Fig. 2a. Osmotherapy 
performed with mannitol increased the brain  Na+ content 
by 6% (p < 0.001), which was less than with NaCl as the 
osmotic agent (15%, p < 0.001), Fig. 2b. The brain  Cl− con-
tent, in contrast, increased to a similar extent upon treat-
ment with either of the osmolytes (31% with NaCl, p < 0.001 
and 38% with mannitol, p < 0.001, Fig. 2c), which was also 
evident for the brain  K+ content (p = 0.23; 2% with NaCl, 
n = 9, p < 0.01, and 3% with mannitol, n = 6, p < 0.001). 
Osmotherapy thus reduced the brain water content, but 
promoted brain electrolyte accumulation (predominantly 
in the form of  Na+ and  Cl−) irrespective of the osmotic 
agent employed, with NaCl being slightly more effective 
than mannitol for brain water extraction under our experi-
mental conditions.
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Inhibitors of ion‑transporting mechanisms 
at the blood‑side membranes of the BBB capillary 
endothelium and choroid plexus had no effect on the brain 
water loss or electrolyte gain upon osmotherapy
To identify the molecular mechanisms governing the 
hyperosmotic-induced brain ion accumulation and 
resulting volume regulation, the experimental regime 
from above (with NaCl as the osmotic agent) was 
repeated in rats during i.v. exposure to a mixture of 
inhibitors targeting a selection of ion-transporting mech-
anisms expressed in the BBB capillary endothelium and 
the blood-facing side of the choroid plexus. The diuretic 
compound bumetanide was applied for NKCC1 inhibi-
tion [25], amiloride to target NHE1 and ENaC [19], while 
the carbonic anhydrase inhibitor methazolamide [16] 
was applied to indirectly inhibit the NBCs. Importantly, 
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Fig. 1 Plasma electrolyte concentrations in response to NaCl osmotherapy (elevated plasma osmolarity). A functional nephrectomy was performed 
in rats prior to i.p. treatment with isosmolar NaCl (control) or hyperosmolar NaCl (osmotherapy) and compared to non-operated naïve rats. a Plasma 
creatinine concentrations (in mM) in naïve rats (0.018 ± 0.001, n = 3), control rats (0.061 ± 0.002, n = 9), and osmotherapy-treated rats (0.063 ± 0.001, 
n = 9). b Plasma urea concentrations (in mM) in naïve rats (4.7 ± 0.2, n = 3), control rats (9.1 ± 0.3, n = 9), and rats exposed to osmotherapy (9.7 ± 0.5, 
n = 9). c Plasma osmolarity (in mOsm) of naïve rats (n = 3), control rats (n = 9), and rats exposed to osmotherapy (n = 9). d, e The plasma electrolyte 
concentrations (in mM) in naïve rats (135.6 ± 0.5  Na+ and 109.0 ± 0.6  Cl−, n = 3), control rats (130.0 ± 0.6  Na+ and 105.6 ± 0.7  Cl−, n = 9) and rats 
exposed to osmotherapy (156.5 ± 0.5  Na+ and 140.7 ± 0.8  Cl−, n = 9). Statistically significant differences were determined by a one-way ANOVA 
with Dunnett’s multiple comparisons post hoc test in a, b and Tukey’s multiple comparisons post hoc test in c–e. Asterisk above the scatter plots 
indicates statistical significance compared to naïve rats (a, b) or control rats (c–e). ***p < 0.001, ns not significant
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these inhibitors did not demonstrate an effect on the 
arterial blood pressure of anaesthetized rats compared 
with vehicle (at 1 h endpoint, n = 3, Fig. 3a).
A single i.v. dose of inhibitors did not alter the 
plasma osmolarity compared to vehicle treatment in 
either control rats (vehicle: 303 ± 1  mOsm vs. inhibi-
tors: 303 ± 2  mOsm, n = 7–9, p = 0.76) or osmother-
apy-treated rats (vehicle: 355 ± 1 mOsm vs. inhibitors: 
357 ± 2  mOsm, n = 8–9, p = 0.35). Delivery of inhibi-
tors did not affect the brain water,  Na+, and  Cl− content 
in control rats and failed to modulate the osmotherapy-
induced changes in brain water,  Na+, and  Cl− content, 
Fig.  3b–d. The  K+ content was also unaffected by i.v. 
inhibitor application (in mmol/kg dry weight: con-
trol; vehicle: 463 ± 2 vs. inhibitors: 460 ± 2, osmoth-
erapy; vehicle: 471 ± 2 vs. inhibitors: 474 ± 2, n = 7–9, 
p > 0.80). To increase the probability for the inhibitors 
to reach their targets in sufficient concentrations, we 
performed an additional experimental series with triple 
inhibitor application (20 min and 5 min prior to initia-
tion of hyperosmotic treatment and 15 min after). These 
increased inhibitor doses did not affect the brain water 
content (Fig. 3b, inset). The unchanged electrolyte con-
tents following inhibitor exposure aligns with the stable 
brain water content. These results suggest that NKCC1, 
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in rats exposed to osmotherapy in the form of NaCl (n = 9) or mannitol (n = 6). The theoretical brain water loss assuming ideal osmotic behavior 
(to 3.24 ml/g dry weight, calculated by Eq. 1) is illustrated as a dashed red line. b, c The brain electrolyte content (in mmol/kg dry weight) 
shown for naïve rats (197 ± 4  Na+ and 141 ± 2  Cl−, n = 3), control rats (197 ± 1  Na+ and 132 ± 3  Cl−, n = 9), and rats exposed to NaCl-mediated 
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groups. *p < 0.05, ***p < 0.001
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NHE1, ENaC, and NBCs localized at the blood-facing 
side of the BBB capillary endothelium and the choroidal 
membrane are not the primary access routes for brain 
electrolyte entry during osmotherapy and therefore not 
the molecular mechanisms underlying brain volume 
regulation under these conditions.
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Fig. 3 Inhibitors of ion-transporting mechanisms at the blood-side membranes do not affect water loss and electrolyte gain. a The arterial blood 
pressure was measured before and until 1 h after i.v. treatment with vehicle or inhibitors (10 mg/kg bumetanide, 6 mg/kg amiloride, and 20 mg/
kg methazolamide). Values are given as the percentage of arterial blood pressure from the last control measurement (corresponding to 30 s before 
i.v. injection). The arterial blood pressure did not differ significantly from control measurements after 1 h (p > 0.90). The end arterial blood pressure 
was unchanged following inhibitor delivery, n = 3 of each, p > 0.90. b The brain water content was unaffected by i.v. inhibitor application in control 
rats [in (ml/g dry weight): vehicle: 3.79 ± 0.01 vs. inhibitors: 3.76 ± 0.01] and in rats subjected to NaCl-mediated osmotherapy (vehicle: 3.46 ± 0.01 vs. 
inhibitors: 3.45 ± 0.02), n = 7–9. Inset: Brain water content in osmotherapy-treated rats exposed to triple doses of vehicle (3.38 ± 0.02) or inhibitors 
(3.38 ± 0.02), n = 4 of each. c The brain  Na+ content (in mmol/kg dry weight) in control rats (vehicle: 197 ± 1 vs. inhibitors: 194 ± 1) and in rats 
exposed to osmotherapy (vehicle: 227 ± 2 vs. inhibitors: 224 ± 3), n = 7–9. d The brain  Cl− content (in mmol/kg dry weight) in control rats (vehicle: 
132 ± 3 vs. inhibitors: 131 ± 4) and in rats exposed to osmotherapy (vehicle: 173 ± 3 vs. inhibitors: 170 ± 4), n = 7–9. Vehicle values from control and 
osmotherapy-treated rats are from Fig. 2a–c and included for comparison. Statistically significant differences were determined by a two-way ANOVA 
with Tukey’s multiple comparisons post hoc test, except for values in the inset of b, which were analyzed using a two-tailed un-paired Student’s 
t-test. ns not significant
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Osmotherapy‑induced brain water loss and ion 
accumulation were unaffected by inhibitors 
of ion‑transporting mechanisms at the CSF‑facing 
choroidal membrane
Ion-transporting mechanisms localized at the other 
major interface; the ventricular side of the choroid plexus, 
may instead contribute to the volume regulatory gain of 
cerebral electrolytes upon administration of osmotherapy 
in the form of a hyperosmotic NaCl challenge. The select 
ion-transporting mechanisms expressed at the luminal 
membrane of the choroid plexus epithelium were tar-
geted by injection of the inhibitor mixture (estimated 
ventricular concentrations of 20 μM bumetanide, 100 μM 
amiloride, and 100 μM methazolamide) directly into one 
of the lateral ventricles. Initially, the maximal inhibitor 
volume and infusion rate were chosen from two criteria: 
(1) both lateral ventricles should be exposed to inhibi-
tors even though injections were given into only one 
of the lateral ventricles (verified with Evans blue, see 
Fig. 4a for a representative image) and (2) the ICP should 
remain fairly stable upon intraventricular inhibitor infu-
sion (the ICP increased briefly to only a minor extent; 
2.6 ± 0.7  mmHg, n = 3, Fig.  4b, with a brief compres-
sion of the jugular vein illustrated as a positive control). 
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Fig. 4 Inhibition of choroidal ion-transporting mechanisms does not affect brain water loss or electrolyte gain. a Representative image of brain 
hemispheres following Evans blue injection into the right lateral ventricle (stained lateral ventricles highlighted in dashed ovals), n = 3. b A 
representative epidural ICP trace with jugular vein compression included as a positive control. The inset shows mean ∆ICP ± SEM (mmHg) during 
intraventricular injection, n = 3. c Brain water content (in ml/g dry weight) of rats treated with intraventricular injections of vehicle or inhibitors 
prior to i.p. administration of isosmolar NaCl (control; vehicle: 3.75 ± 0.01 vs. inhibitors: 3.74 ± 0.02) or hyperosmolar NaCl (osmotherapy; vehicle: 
3.42 ± 0.01 vs. inhibitors: 3.44 ± 0.03), n = 6 of each. d The brain  Na+ content (in mmol/kg dry weight) in control rats treated with vehicle (200 ± 1) 
or inhibitors (197 ± 3) and in osmotherapy-treated rats exposed to vehicle (224 ± 3) or inhibitors (224 ± 3), n = 6 of each. e The brain  Cl− content 
(in mmol/kg dry weight) in control rats treated with vehicle (162 ± 3) or inhibitors (166 ± 3) and in osmotherapy-treated rats exposed to vehicle 
(198 ± 4) or inhibitors (203 ± 2), n = 6 of each. Statistical significant differences were determined by a two-way ANOVA with Tukey’s multiple 
comparisons post hoc test. ns not significant
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Vehicle or inhibitors were thus injected into the ventricu-
lar system of anesthetized rats prior to osmotherapy fol-
lowed by another drug application every 15 min during 
the 1 h experimental time period to maintain a maximal 
targeting effect despite risk of wash-out by the high ven-
tricular CSF flow rate [26]. The plasma osmolarity was 
similar in vehicle- and inhibitor-treated rats exposed 
to isosmolar NaCl solution (vehicle: 297 ± 2  mOsm vs. 
inhibitors: 298 ± 2  mOsm, n = 6, p = 0.94) and in rats 
subjected to osmotherapy (vehicle: 347 ± 1  mOsm vs. 
inhibitors: 347 ± 2 mOsm, n = 6, p = 0.87). Osmotherapy 
led to a reduction in the brain water content and to an 
increased  Na+ (12%) and  Cl− (22%) content in the brain 
of vehicle-treated rats (n = 6, p < 0.001 for both, Fig. 4c–
e), with an unaltered brain  K+ content (in mmol/kg dry 
weight: control: 472 ± 3 vs. osmotherapy: 471 ± 4, n = 6, 
p > 0.90). Intraventricular inhibitor application had no 
effect on the brain water content in control rats or in 
osmotherapy-treated rats, Fig. 4c. The brain  Na+ and  Cl− 
content in control- or osmotherapy-treated rats was, like-
wise, unaffected by inhibitor application into the lateral 
ventricles (n = 6, for all conditions, Fig. 4d, e), which was 
also seen for brain  K+ content (in mmol/kg dry weight: 
control; vehicle: 472 ± 3 vs. inhibitors: 469 ± 4, osmother-
apy; vehicle: 471 ± 4 vs. inhibitors: 472 ± 2, n = 6, p > 0.90 
for both). These results suggest that osmotherapy-medi-
ated brain electrolyte influx does not originate from 
increased activity of choroidal transporters (NKCC1, 
NHE1, NBCs, or ENaC) expressed at the luminal CSF-
facing side of the membrane.
The integrity of the brain barriers was preserved 
after osmotherapy treatment
To assess whether  Na+ and  Cl− entered the brain 
through a possible breach in the brain barriers in 
response to osmotherapy, we delivered  Na+-fluorescein 
i.v. 5  min prior to osmotherapy treatment (as above). 
Histological analysis of coronal brain sections (Fig. 5a) 
from the control rats revealed a weak background fluo-
rescent signal in the brain parenchyma, as illustrated 
before [23], near-absence of  Na+-fluorescein in the 
neocortex, hippocampus, and thalamus, and minor 
staining in the lateral ventricle [23] (from choroid 
plexus with fenestrated blood capillaries), n = 3, Fig. 5c. 
Notably, the observed staining pattern was unaltered by 
osmotherapy treatment as illustrated in representative 
images of the neocortex, hippocampus, thalamus, and 
lateral ventricle, while no fluorescence was detected 
in naïve rats, which did not receive  Na+-fluorescein 
(n = 3, Fig.  5b–d). The pineal gland (Fig.  5e) served as 
region of interest naïve control osmotherapy
Fig. 5 Osmotherapy does not alter the brain barrier permeability.  Na+-fluorescein (green fluorescence) was injected into the blood circulation 
of rats prior to i.p. exposure of isosmolar NaCl (control) or hyperosmolar NaCl (osmotherapy). Naïve rats did not receive  Na+-fluorescein and were 
euthanized immediately after anaesthesia induction. a, e Phase contrast images illustrate structures of the brain regions of interest in transmitted 
white light. Representative images of  Na+-fluorescein in b–d hippocampus, thalamus, neocortex, and the lateral ventricle (LV) and f–h pineal gland 
(positive control) of naïve rats, control rats, and osmotherapy-treated rats, n = 3. Scale bar = 500 μm
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a positive control due to the lack of BBB in this brain 
structure. Hence,  Na+-fluorescein was detected in 
the pineal gland of control rats and osmotherapy-
treated rats, while no fluorescence was observed in 
the pineal gland of naïve rats, which did not receive 
 Na+-fluorescein (n = 3, Fig.  5f–h). The absence of 
osmotherapy-induced penetration of  Na+-fluorescein 
into the brain indicates that the integrity of the BBB 
and BCSFB remained intact during the applied osmo-
therapy treatment.
Discussion
We have demonstrated in rats that following osmother-
apy (~ 50 mOsm increase in plasma osmolarity), water is 
osmotically extracted from the brain, although to a lesser 
extent than can be predicted from theoretical calcula-
tions. The reduced osmotic extraction was assigned pre-
dominantly to brain  Na+ and  Cl− accumulation (6–15% 
for  Na+ and 22–38% for  Cl−) and to a minor extent, if any, 
brain  K+ accumulation (up to 3% increase) as a function 
of increased plasma osmolarity, in agreement with an 
earlier report [14]. Notably, it is not simply the ion con-
centration that increases with the systemic hyperosmo-
larity but the actual ion content. These findings indicate 
that specific volume regulatory transporting mechanisms 
are activated in response to and/or as a consequence of 
increased plasma osmolarity. Employment of NaCl as the 
osmotic agent contributed to an increased  Na+ and  Cl− 
concentration in the plasma, which, in itself, could affect 
the brain electrolyte content. However, we observed that 
mannitol-mediated osmotherapy of identical magnitude 
and delivered volume led to similar effects on the brain 
electrolyte/water content [14], indicating that plasma 
hyperosmolarity, and not the increased plasma  Na+ and 
 Cl− concentrations, causes the brain electrolyte accumu-
lation. Osmotic extraction of cerebral fluid was slightly 
more effective with NaCl as the osmotic agent, rather 
than mannitol, even though the cerebral accumulation 
of  Na+ was significantly higher in rats treated with NaCl. 
The reduced osmotic fluid extraction (and thus osmolyte 
increase) observed with mannitol as the osmotic agent 
may instead be explained by an unknown but substan-
tial influx of other osmolytes, e.g. mannitol itself, which 
has previously been detected in the rat brain follow-
ing mannitol-induced elevation in the plasma osmolar-
ity [14]. With the similar  Cl− accumulation obtained 
with both NaCl and mannitol as the osmotic agent, one 
may, however, from the principle of electroneutrality, 
expect accumulation of another cationic electrolyte (or 
reduced retention of a different anion). Taken together, 
our findings indicate that the osmotherapy-induced 
rebound response may be regulated differently depend-
ing on the osmotic agent applied, although overlapping 
mechanisms, such as the observed gain of brain  Na+ and 
 Cl−, clearly exist.
According to theoretical considerations based on 
reflection coefficients of both osmotic agents, i.e. the 
relative impermeability across the BBB, NaCl treatment 
has been predicted to induce a larger osmotic response 
than mannitol [27], as confirmed by our findings. While 
previous findings demonstrated that NaCl was superior 
with regard to initial reduction of the ICP, maintenance 
of a lowered ICP [28, 29], and an increased cerebral 
water loss [29] in experimental animal models of brain 
injuries, other researchers observed an equal efficiency 
of NaCl or mannitol as the osmotic agent [30, 31], or a 
higher efficiency with mannitol in healthy animals [32]. 
Two of the latter observations may, however, be influ-
enced by the unequal end plasma osmolarity induced by 
either osmotic agent [30, 32], which essentially prevents a 
comparative analysis. A line of clinical trials, mainly per-
formed on patients with traumatic brain injury, reported 
that osmotherapy using NaCl solutions with additives 
(e.g. dextran, lactate, or hydroxyethyl starch solutions) 
[33–35] or NaCl alone [36] more effectively lowered the 
ICP compared with mannitol. While these reports sup-
port the findings from our animal experiments, two other 
clinical trials found an equal efficacy of the two osmotic 
agents on the ICP [37, 38]. However, a direct comparison 
between the few head-to-head studies carried out is chal-
lenged by the varying treatment strategies; (i) continuous 
or bolus injections, (ii) different doses/volumes of the 
osmotic agent, and (iii) different time windows, which 
altogether resulted in variable plasma osmolarities. In 
addition, diverse patient populations and outcome meas-
urements [39] further hamper the comparison between 
clinical trials. It is, therefore, still questionable which 
osmotic agent is superior [1, 40] and animal/clinical stud-
ies, which allow direct comparison, are warranted. Man-
nitol remains the recommended standard osmotic agent 
for treatment of patients with severe head injury (Level 
II evidence), whereas hyperosmolar NaCl is recom-
mended for children (Level III evidence) [41]. The choice 
of osmotic agent may, however, rather be based on side-
effect profiles of the osmotic agents and how those will 
affect the clinical situation (comorbidities, age) [1].
Neither the signaling cascades, nor the molecular 
transport mechanisms, that couple systemic plasma 
hyperosmolarity to brain electrolyte accumulation have 
been identified. In the present study, we therefore intro-
duced a mixture of inhibitors targeting ion-transporting 
proteins expressed in the BBB capillary endothelium 
and/or the choroid plexus epithelium, and determined 
their effect on osmotherapy-induced brain ion accumu-
lation. While amiloride and methazolamide may tar-
get abluminal ion-transporting mechanisms [21, 42], 
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we expect insignificant bumetanide interaction at the 
abluminal membrane of the capillaries forming the BBB 
because of its poor BBB permeability [43, 44]. We failed 
to detect evidence in favor of NKCC1, NHE1, ENaC or 
carbonic anhydrase (indirectly targeting the bicarbo-
nate transporters) located at the BBB endothelium or in 
choroid plexus participating in this brain volume regu-
lation. Hence, we were unable to reproduce a previously 
reported reduction of hyperosmotic plasma-induced 
brain water extraction by methazolamide [14]. The rea-
sons for this discrepancy are unclear, although the previ-
ous study employed a very high dose of methazolamide, 
which was delivered i.p. instead of i.v. as in the present 
study. We cannot rule out that the inhibitor concentra-
tions applied in this study were not sufficient for effective 
blockage of the target proteins, even though a procedure 
with triple doses was incorporated to enhance inhibitor 
efficiency. The free unbound inhibitor concentration may, 
however, be significantly reduced by potential binding of 
inhibitors to plasma proteins, as shown for bumetanide 
[45]. We recently found that hyperosmotic conditions 
enhanced the activity of abluminal  Na+/K+-ATPase in 
endothelial cells, which were co-cultured with astrocytes 
in an in vitro BBB model [46], indicating that this trans-
port mechanism may counteract osmotic extraction from 
the brain by cerebral accumulation of  Na+ in response to 
a hyperosmotic challenge. With the damaging effect of 
pump inhibition, it is, however, not simple to verify this 
finding by currently available techniques in animal mod-
els in vivo: a direct effect of  Na+/K+-ATPase inhibition is 
difficult to deduce, due to disruption of electrochemical 
gradients controlling secondary active and passive trans-
porting mechanisms. The  Na+/K+-ATPase expressed at 
the CSF-facing membrane of the choroid plexus could 
also be a potential candidate in brain volume regulation 
upon osmotherapy, since the  Na+/K+-ATPase may con-
tribute to CSF production [47], in addition to the recently 
reported significant contribution of NKCC1 in murine 
CSF production [48]. To this end, it is important to note 
that the wet-dry technique, employed to determine brain 
water content, favors parenchymal water content over 
CSF, as the major part of CSF is lost in the brain isola-
tion process. If the ion-transporting mechanisms were to 
regulate the CSF production per se, and the equilibrium 
rate between CSF and brain interstitial fluid is slow, such 
regulatory functions could well be missed by this experi-
mental design.
While the ion-transporting mechanisms (NKCC1, 
NHE1, NBCs, and ENaC) at the BBB capillary endothe-
lium and choroid plexus epithelium were shown not to 
be involved in the osmotherapy-mediated translocation 
of  Na+ and  Cl− from the blood into the rat brain under 
our experimental conditions,  Na+ and  Cl− could instead 
enter the brain via paracellular transport routes, which 
may become available with hyperosmolar plasma. How-
ever, we demonstrated that the two major brain barri-
ers, i.e. the BBB and BCSFB, appeared to remain intact 
upon osmotherapy, as we detected no changes in cer-
ebral  Na+-fluorescein accumulation whether or not 
the animals had been exposed to osmotherapy. Nota-
bly, we cannot exclude that  Na+ and  Cl−, which are of a 
smaller molecular weight (22.99  Da and 35.45  Da) than 
 Na+-fluorescein (376.27 Da), can cross the brain barriers 
via a paracellular route provided that the given hyperos-
motic challenge promoted an increase in the permeabil-
ity of the brain barriers towards smaller permeants, while 
excluding the fluorescent dye. However, a previous study 
showed that a change in barrier function, correspond-
ing to BBB opening towards mannitol and  Na+, occurred 
only with hyperosmotic challenges rendering the plasma 
osmolarity > 385  mOsm [49]. An alternative manner of 
accumulating brain electrolytes during conditions of ele-
vated plasma osmolarity could be via increased bulk flow 
of CSF into the brain interstitial fluid [50] or via a poten-
tial regulation of fluid drainage at arachnoid granulations 
[51], dural lymphatic vessels [52, 53], and/or at glym-
phatic paravascular drainage routes [54]. Parenchymal 
cell volume regulation may, in addition, indirectly affect 
electrolyte movement across the brain barriers.
The present experimental protocol was designed 
to quantitatively resolve the direct consequences of 
increased plasma osmolarity (mimicked osmotherapy) 
on brain water and ion accumulation (hence the choice 
of nephrectomized animals, in which the inflicted change 
in plasma osmolarity could be tightly controlled). In vari-
ous severities of stroke-induced brain edema in animal 
models, one may well expect altered BBB integrity (in the 
afflicted area) and potentially even altered expression/
activity of membrane transporters in the BBB capillary 
endothelium. Such stroke-induced membrane transport 
responses could potentially affect ion and water accumu-
lation during osmotherapy, and may serve to explain the 
observed beneficial effect of bumetanide treatment in an 
animal stroke model [11]. Future studies should therefore 
address whether the osmotherapy-mediated influx of 
cerebral  Na+ and  Cl− likewise contribute to the rebound 
response in animal models of stroke-induced cerebral 
edema.
Conclusions
While osmotherapy immediately lowers the ICP of 
patients with cerebral edema, a delayed rebound 
response can limit or even reverse the otherwise effec-
tive drainage. We here demonstrated that the mam-
malian brain loses less water than predicted from 
osmotically obliged water extraction when exposed to 
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hyperosmolar plasma; osmotherapy. This volume regu-
latory mechanism, the rebound effect, hinges on initia-
tion of brain ion accumulation predominantly in the 
form of  Na+ and  Cl−. We propose that the brain ion 
accumulation occurs via transcellular pathways, one 
of which may well be hyperosmolar-induced ablumi-
nal  Na+/K+-ATPase activity [46], rather than due to 
a hyperosmolar-induced breach in the brain barriers. 
In the absence of identified luminal transport mecha-
nisms, altered bulk flow (CSF-to-parenchyma flow) or 
drainage ((g)lymphatic pathways) may well contribute 
to osmolarity-induced brain electrolyte accumulation. 
The transport mechanisms proposed to promote osmo-
therapy-induced brain ion accumulation remain unre-
solved, since we found no evidence of NKCC1, NHE1, 
ENaC, and NBCs appearing amongst these under our 
experimental conditions in healthy non-edematous 
rats. Future identification of such ion-transporting 
mechanisms might provide a useful therapeutic target 
for pharmacological prevention of the rebound effect 
during osmotherapy in patients experiencing brain 
edema.
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